UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT FILED PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT
(DATE OF EARLIEST EVENT REPORTED): JULY 15, 2002
ZONAGEN, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
DELAWARE 0-21198 76-0233274
(STATE OR OTHER JURISDICTION OF (COMMISSION FILE NUMBER) (I.R.S. EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION)
2408 TIMBERLOCH PLACE, SUITE B-4
THE WOODLANDS, TEXAS 77380
(ADDRESS OF PRINCIPAL
EXECUTIVE OFFICES
AND ZIP CODE)
(281) 367-5892
(REGISTRANT'S TELEPHONE NUMBER,
INCLUDING AREA CODE)
ITEM 5. OTHER EVENTS
On July 15, 2002, Zonagen, Inc. issued a press release announcing that
the Company and Schering-Plough Corporation have mutually agreed to terminate
the worldwide licensing agreements that cover Zonagen's phentolamine based
technologies for sexual dysfunction including VASOMAX(TM). The agreements had
been in place since November 14, 1997. The technology was returned to Zonagen
for undisclosed present and future considerations.
The press release is filed as an exhibit to this Current Report on Form
8-K and is incorporated by reference herein.
ITEM 7. EXHIBITS
Exhibit 99.1 -- Press Release dated July 15, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: July 15, 2002.
By: /s/ Louis Ploth, Jr.
----------------------------------------
Louis Ploth, Jr.
Vice President, Business Development and
Chief Financial Officer
EXHIBIT INDEX
Exhibit
Number Description
------- ------------
99.1 Press Release dated July 15, 2002.